Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SVRA
SVRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SVRA News
Savara Secures $150M Non-Dilutive Capital for MOLBREEVI Launch
Jan 27 2026
Newsfilter
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses
Jan 24 2026
Globenewswire
Savara Submits MOLBREEVI BLA for Autoimmune PAP Treatment, Targeting FDA Approval
Jan 08 2026
Newsfilter
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Savara Resubmits MOLBREEVI BLA with Fujifilm as Manufacturer, Requests Priority Review
Dec 26 2025
Newsfilter
BofA Raises ArcBest Price Target to $84 Amid Neutral Rating
Dec 23 2025
Benzinga
Savara Resubmits MOLBREEVI Application to FDA Seeking Priority Review
Dec 23 2025
NASDAQ.COM
Savara Refiles MOLBREEVI BLA with FDA, Requests Priority Review
Dec 22 2025
SeekingAlpha
Savara Inc. to Present MOLBREEVI Progress at 44th J.P. Morgan Healthcare Conference
Dec 17 2025
Newsfilter
Savara Secures European Patent for MOLBREEVI Until March 2041
Dec 11 2025
Newsfilter
Savara and PARI Awarded European Patent for Drug-Device Combination
Dec 02 2025
Yahoo Finance
Savara Inc. Rises in Value Amid Acquisition Rumors
Dec 02 2025
SeekingAlpha
Major Stocks Including Micron, Endeavour Silver, First Majestic Silver, and Applied Digital Experience Gains on Friday
Nov 28 2025
Benzinga
Oppenheimer Upgrades Savara to Outperform and Increases Price Target to $9
Nov 14 2025
Benzinga
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
Nov 07 2025
PRnewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
Nov 07 2025
PRnewswire
Show More News
